MGL 3196

Drug Profile

MGL 3196

Alternative Names: MGL-3196; THR beta agonists - VIA Pharmaceuticals; VIA-3196

Latest Information Update: 14 Jan 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Madrigal Pharmaceuticals
  • Class Antihyperglycaemics; Antihyperlipidaemics; Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperlipoproteinaemia type IIa; Non-alcoholic steatohepatitis
  • No development reported Dyslipidaemias; Hypercholesterolaemia; Hypertriglyceridaemia

Most Recent Events

  • 03 Apr 2017 Madrigal Pharmaceuticals plans a phase II trial for Hyperlipoproteinaemia type IIa (homozygous familial hypercholesterolaemia)
  • 03 Apr 2017 Madrigal Pharmaceuticals plans pivotal phase III trials for Non-alcoholic steatohepatitis and Hyperlipoproteinaemia type IIa
  • 16 Jan 2017 Phase-II clinical trials in Hyperlipoproteinaemia type IIa (Adjunctive treatment) in Denmark (PO) (EudraCT2016-002315-17)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top